Aurantio-obtusin
Based on 1 publication(s) in Google Scholar
Aurantio-obtusin is a anthraquinone compound that can be extracted from cassia seed. Aurantio-obtusin has the effects of decreasing blood pressure, decreasing blood lipids and anti-inflammatory.Aurantio-obtusin is an orally active vasodilator. Aurantio-obtusin ameliorates hepatic steatosis through AMPK/ autophagy- and AMPK/TFEB mediated inhibition of lipid accumulation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.39%
- CAS. Nr.: 67979-25-3
- Formel: C17H14O7
- Molecular Weight:330.29
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Aurantio-obtusin
MoreAlle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Aurantio-obtusin (6.25-100 μM; 24 h) significantly decreases the production of NO and PGE2, and inhibits the expression of IL-6, TNF-α, COX-2 protein in RAW264.7 cells treated with LPS (0.2µg/mL)[2].
Aurantio-obtusin (6.25-100 μM; 12 h) inhibits the activation of NF-κ B by inhibiting the phosphorylation of i-κB and IKK in RAW264.7 cells treated with LPS (0.2µg/mL)[1].
Aurantioobtusin (1-10000 nM) induces small resistance vasodilation in rat MA in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Aurantio-obtusin (5-15 mg/kg; Oral administration; A single dose) inhibits fatty acid synthesis, promotes FAO and activates AMPK signaling and autophagy in HFSW-induced mice [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice model[3]
-
Dosage:5 mg/kg, 10 mg/kg, 15 mg/kg
-
Administration:Oral gavage (p.o.), feeding with HFSW diet for 4 weeks then giving different dose of Aurantio-obtusin for another 4 weeks.
-
Result:Decreased the levels of TG and TC in liver and TG, ALT and AST in serum induced by HSFW.
Reduced the number and size of fat droplets in liver cells.
Significantly increased AMPK phosphorylation in HFSW-induced mice.
Chemical Information
-
CAS. Nr. 67979-25-3
-
Appearance Solid
-
Molecular Weight 330.29
-
Formel C17H14O7
-
Color Yellow to orange
-
SMILES
O=C1C2=C(C=C(C)C(O)=C2OC)C(C3=CC(O)=C(OC)C(O)=C13)=O
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochem Genet
Aurantio-obtusin Alleviates Dry Eye Disease by Targeting NF-κB/NLRP3 Signaling in Rodent Models. [Abstract]2024 Apr;62(2):1-14. PMID: 37633872
Lösungsmittel & Löslichkeit
DMSO : 25 mg/mL (75.69 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Li, Shuzhen, et al. Aurantio-obtusin relaxes systemic arteries through endothelial PI3K/AKT/eNOS-dependent signaling pathway in rats. Journal of pharmacological sciences vol. 128,3 (2015): 108-15. [Content Brief]
[2]. Hou Jingyi, et al. Anti-Inflammatory Effects of Aurantio-Obtusin from Seed of Cassia obtusifolia L. through Modulation of the NF-κB Pathway. Molecules (Basel, Switzerland) vol. 23,12 3093. 27 Nov. 2018. [Content Brief]
[3]. Zhou Fei, et al. Aurantio-Obtusin Attenuates Non-Alcoholic Fatty Liver Disease Through AMPK-Mediated Autophagy and Fatty Acid Oxidation Pathways. Frontiers in pharmacology vol. 12 826628. 11 Jan. 2022. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0276 mL | 15.1382 mL | 30.2764 mL | 75.6911 mL |
| 5 mM | 0.6055 mL | 3.0276 mL | 6.0553 mL | 15.1382 mL | |
| 10 mM | 0.3028 mL | 1.5138 mL | 3.0276 mL | 7.5691 mL | |
| 15 mM | 0.2018 mL | 1.0092 mL | 2.0184 mL | 5.0461 mL | |
| 20 mM | 0.1514 mL | 0.7569 mL | 1.5138 mL | 3.7846 mL | |
| 25 mM | 0.1211 mL | 0.6055 mL | 1.2111 mL | 3.0276 mL | |
| 30 mM | 0.1009 mL | 0.5046 mL | 1.0092 mL | 2.5230 mL | |
| 40 mM | 0.0757 mL | 0.3785 mL | 0.7569 mL | 1.8923 mL | |
| 50 mM | 0.0606 mL | 0.3028 mL | 0.6055 mL | 1.5138 mL | |
| 60 mM | 0.0505 mL | 0.2523 mL | 0.5046 mL | 1.2615 mL |
Aurantio-obtusin Related Classifications
HY-N0261 Related Classifications
Powered by Bioz